Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma
Conference call scheduled for tomorrow, Tuesday, December 11, 2007 at 8:45 am
ET
PRINCETON, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX)
and Bristol-Myers Squibb Company (NYSE: BMY) today announced top-line data from the
three registrational trials (008, 022, 007) that constitute the monotherapy program
for ipilimumab -- an investigational immunotherapy -- in patients with metastatic
melanoma. The results from study 008, conducted under Special Protocol Assessment
(SPA), did not meet the primary endpoint, which was to rule out a best objective
response rate of less than 10 percent. However, the totality of data from the
registrational program included a clear dose response effect observed in study 022
and best objective response rates across the three studies ranging from mid-single
digits to mid-teens as determined by independent radiology review.
The objective responses were consistent with previous observations and included
complete and partial responses. The majority of the responses were ongoing at the
end of the observation period. In contrast to standard cytotoxic therapy, responses
at the highest doses were noted to evolve over time; these patterns of response
appear potentially unique to this form of therapy.
Given the importance of these findings and the limited treatment options for
this patient population, Medarex and Bristol-Myers Squibb are planning to meet with
regulatory agencies in the near future. Pending these discussions, the companies
aim to submit a regulatory filing to the U.S. Food and Drug Administration (FDA) in
the first half of 2008.
Overall, the safety results from the three studies were generally consistent
with data from previously reported clinical trials of ipilimumab and, as expected,
the most common immune related adverse events (greater than five percent) consisted
of rash, diarrhea, and hepatitis. Safety data from the 10 mg/kg cohorts were
consistent with results from similar or lower doses of previously reported clinical
data.
About the Ipilimumab Registrational Monotherapy Program
The registrational, monotherapy program evaluated ipilimumab in 487 patients
with advanced Stage III or Stage IV metastatic melanoma from three clinical trials
conducted at multiple centers across North America, Europe, South America and
Africa. The trials included an open-label, single arm trial (008) evaluating overall
response rate in 155 patients who progressed on or following standard treatment; a
randomized, double-blind trial (022) evaluating the efficacy of three dose levels of
ipilimumab in 216 patients who were previously treated, relapsed or failed to
respond to experimental treatment or were unable to tolerate currently approved
therapies; and a randomized, double-blind, placebo-controlled trial (007) in 116
patients comparing the safety of ipilimumab, with or without prophylactic oral
budesonide (primarily evaluating the rate of grade 2+ diarrhea). All patients
enrolled in these trials were diagnosed with advanced Stage III or Stage IV
malignant melanoma.
All three studies were designed to capture clinical activity and kinetics of
response at specific time points, beginning with an initial assessment at 12 weeks.
Objective response determinations were verified by an independent radiology
committee. Active follow-up of patients is ongoing, and many patients enrolled in
the three studies are continuing to be treated with maintenance therapy.
Initiation of the ipilimumab registrational monotherapy program reviewed under
SPA with the FDA was announced in March 2006. Following the March 2006 announcement,
enrollment of 487 patients was completed in less than one year and in line with
timeline expectations. In December 2006, ipilimumab received Fast Track designation
from the FDA for use as a monotherapy in previously treated patients with metastatic
melanoma.
About Ipilimumab
Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T
lymphocyte-associated antigen 4), a molecule on T-cells that plays a critical role
in regulating natural immune responses. The absence or presence of CTLA- 4 can
augment or suppress the immune system's T-cell response in fighting disease.
Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active
immune response in its attack on cancer cells.
Comprehensive Clinical Trial Program for Ipilimumab
Ipilimumab is being developed through a joint partnership between Bristol- Myers
Squibb and Medarex. Based on nonclinical and clinical studies showing that antibody
blockade of CTLA-4 plays an important role in sustaining an active immune response
to fight cancer, Bristol-Myers Squibb and Medarex are pursuing a broad clinical
development program with ipilimumab evaluating its potential use in advanced
metastatic melanoma, as well as prostate, lung, pancreatic, bladder, breast,
lymphoma and leukemia cancers. More than 2,000 patients have been treated with
ipilimumab as a monotherapy or in combination with other agents in clinical trials.
For further information about ipilimumab clinical trials, please visit
www.clinicaltrials.gov.
About Advanced Melanoma
Melanoma is a form of skin cancer characterized by the uncontrolled growth of
pigment-producing cells (melanocytes) located in the skin. As with many cancers, it
is more difficult to treat once the disease has spread beyond the skin to other
parts of the body by way of the bloodstream or the lymphatic system (metastatic
disease). Melanoma accounts for about three percent of skin cancer cases, but it
causes most skin cancer deaths. The American Cancer Society estimates that in 2007
there will be 59,940 new cases of melanoma in the U.S., and about 8,110 people will
die of this disease.
Conference Call Details for Tomorrow, December 11, 2007 at 8:45 am ET
Medarex will hold a public conference call on Tuesday, December 11, 2007 at 8:45
am Eastern Time to discuss the top-line results of the registrational program. To
access the call live, please dial 1-888-713-4214 within the U.S. or 1-617-213-4866
outside the U.S. The conference call passcode number is 37954707. The live webcast
of the conference call can be accessed at www.medarex.com/Investor/Webcasts.htm. An
archive of the event will be available for a limited period following the call and
may be accessed at www.medarex.com or by dialing 1-888-286-8010 within the U.S. or
1-617-801-6888 outside the U.S. The archive conference call passcode number is
71497127.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and
potential commercialization of fully human antibody-based therapeutics to treat
life-threatening and debilitating diseases, including cancer, inflammation,
autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R)
technology and product development and clinical manufacturing experience to
generate, support and potentially commercialize a broad range of fully human
antibody product candidates for itself and its partners. More than 30 of these
therapeutic product candidates derived from Medarex technology are in human clinical
testing or have had INDs submitted for such trials, with seven of the most advanced
product candidates currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building value by
developing a diverse pipeline of antibody products to address the world's unmet
healthcare needs. For more information about Medarex, visit its Web site at
www.medarex.com.
Medarex Statement on Cautionary Factors: Except for the historical information
presented herein, matters discussed herein may constitute forward- looking
statements that are subject to certain risks and uncertainties that could cause
actual results to differ materially from any future results, performance or
achievements expressed or implied by such statements. Statements that are not
historical facts, including statements preceded by, followed by, or that include the
words "potential"; "believe"; "plan"; "expect"; "estimate"; "could"; "may"; or
similar statements are forward- looking statements. Medarex disclaims, however, any
intent or obligation to update these forward-looking statements. Risks and
uncertainties include risks associated with whether future clinical trials will
result in the same outcomes as these clinical trials and whether the regulatory
authorities will interpret the data from these clinical trials in the same manner,
as well as risks detailed from time to time in Medarex's public disclosure filings
with the U.S. Securities and Exchange Commission (SEC), including its Annual Report
on Form 10-K for the fiscal year ended December 31, 2006 and its quarterly reports
on Form 10-Q. There can be no assurance that such development efforts will succeed
or that other developed products will receive required regulatory clearance or that,
even if such regulatory clearance were received, such products would ultimately
achieve commercial success. Copies of Medarex's public disclosure filings are
available from its investor relations department.
About Bristol-Myers Squibb
Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive
exploration of innovative cancer fighting therapies designed to extend and enhance
the lives of patients living with cancer. More than 40 years ago, Bristol-Myers
Squibb built a unified vision for the future of cancer treatment. With expertise,
dedication and resolve, that vision led to the development of a diverse global
portfolio of anti-cancer therapies that are an important cornerstone of care today.
Hundreds of scientists in Bristol-Myers Squibb's Research and Development
organization are studying ways to improve current cancer treatments and identify
better, more effective medicines for the future.
Bristol-Myers Squibb is a global pharmaceutical and related health care products
company whose mission is to extend and enhance human life.
This press release contains "forward-looking statements" as that term is defined
in the Private Securities Litigation Reform Act of 1995, regarding the development
of biological products and the submission of applications to market such products.
Such forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay, divert or
change any of them, and could cause actual outcomes and results to differ materially
from current expectations. No forward-looking statement can be guaranteed. Among
other risks, there can be no guarantee that the development of the product described
in this release will be successful or that the clinical studies described in this
release will support the filing of a Biological License Application (BLA) with the
U.S. Food and Drug Administration (FDA). Furthermore, there can be no assurances
that if a BLA is filed with the FDA, that it will be filed in the timeframe
described in this release or that the BLA for the product described in this release
will receive regulatory approval. There can be no assurances that if approved, the
product described in this release will be commercially successful. Forward-looking
statements in the press release should be evaluated together with the many
uncertainties that affect Bristol-Myers Squibb's business, particularly those
identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual
Report on Form 10-K for the year ended December 31, 2006, its Quarterly Reports on
Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement, whether as a result of
new information, future events, or otherwise.
SOURCE Bristol-Myers Squibb Company; Medarex, Inc.
-0- 12/10/2007
/CONTACT: Media, Jean Mantuano, +1-609-430-2880, Ext. 2221, or Investor
Relations, Laura Choi, +1-609-430-2880, Ext. 2216, both of Medarex; or Media,
Madeline Malia, +1-609-252-3347 or +1-609-651-1323, Madeline.Malia@bms.com, or
Investors, John Elicker, +1-212-546-3775, John.Elicker@bms.com, both of
Bristol-Myers Squibb/
/Web site: http://www.bms.com
http://www.medarex.com
http://www.clinicaltrials.gov /
(BMY MEDX)
CO: Bristol-Myers Squibb Company ST: New Jersey IN: MTC HEA SU: SVY TRI CCA
MV-FB -- NYM166 -- 2037 12/10/2007 16:26 EST http://www.prnewswire.com
©2001-2008 Medarex, Inc. All rights reserved.